Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pfizer's Essential Health Leadership On Why US Biosimilars Will Take Off – Eventually

Apr 11 2018

• By Jessica Merrill

New York, July 19, 2016: Corporate lettering on the exterior of the Pfizer headquarters in Manhattan.

Related Content

Humira's 'Unique' Number Of Patents Makes Biosimilar Entry Risky, Pfizer Says

Apr 11 2018

Pfizer v. J&J Sets Stage For Biosimilar Showdown Over Exclusive Contracts

Sep 21 2017

Hospira Bulks Up Pfizer’s Established Products Unit, But Won’t Speed A Split

Feb 09 2015

Payers Like Biosimilars, But Rebates Remain The Bottom Line (For Now)

Nov 29 2017

Pfizer Will Support Inflectra Launch With Dedicated Sales Force

Nov 14 2016

Appointments: Pfizer, Lilly, Theramex, Evox Therapeutics, Syros, Spruce Biosciences, Rexgenero

Nov 14 2017

End In Sight: Humira Stacks Up 20 Years Of US Market Exclusivity

Apr 05 2018

Related Companies

Pfizer Inc.

Johnson & Johnson

Hospira, Inc.

Celltrion, Inc.

AbbVie Inc.

Amgen, Inc.

Samsung Bioepis Co., Ltd.

Additional Topics

United States Europe Biosimilars Business Strategies Commercial BioPharmaceutical

More from Strategy

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window